Intra Cellular Therapies | Omløpsmidler



Current Assets Endring Dato
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Biogen USD 7.46B 626.3M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Cytokinetics USD 1.11B 89.34M 2024-12
Gilead Sciences USD 19.17B 4.39B 2024-12
Halozyme Therapeutics USD 1.09B 41.64M 2024-12
Intra Cellular Therapies USD 1.31B 35.63M 2024-12
J&J USD 55.89B 2.64B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Prothena USD 485.41M 49.57M 2024-12
RedHill Biopharma USD 15.7M 3K 2024-06
Supernus Pharmaceuticals USD 686.07M 46.07M 2024-12
United Therapeutics USD 3.87B 126.5M 2024-12



Intra Cellular Therapies Omløpsmidler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.